Alnylam Pharmaceuticals (ALNY) Treasury Shares (2011 - 2025)
Alnylam Pharmaceuticals (ALNY) posted Treasury Shares of $779000.0 for Q4 2025, down 54.84% on a QoQ basis from $1.7 million in Q4 2024, and down 54.84% year-over-year from $1.7 million in Q4 2024.
Alnylam Pharmaceuticals (ALNY) Treasury Shares (2011 - 2025) Analysis & Trends
Alnylam Pharmaceuticals' Treasury Shares history runs 14 years deep, the most recent figure standing at $779000.0 for Q4 2025.
- Quarterly Treasury Shares fell 54.84% year-over-year to $779000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $779000.0 (down 54.84% YoY) and the FY2025 annual result came in at $779000.0, down 54.84% from the prior year.
- Treasury Shares was $779000.0 for Q4 2025 at Alnylam Pharmaceuticals, down from $1.7 million in the prior quarter.
- Across five years, Treasury Shares topped out at $1.7 million in Q4 2024 and bottomed at $779000.0 in Q4 2025.
- A 5-year average of $1.2 million and a median of $1.1 million in 2021 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2021 — Treasury Shares soared 870.94% — and 2025, when it plunged 54.84%.
- Alnylam Pharmaceuticals' Treasury Shares stood at $1.1 million in 2021, then advanced by 5.19% to $1.2 million in 2022, then decreased by 14.23% to $1.0 million in 2023, then soared by 68.29% to $1.7 million in 2024, then plunged by 54.84% to $779000.0 in 2025.
- Business Quant data shows ALNY's Treasury Shares at $779000.0 in Q4 2025, $1.7 million in Q4 2024, and $1.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 265,401.92 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 34.70 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 5.14 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 779,000.00 |
| Dec 31, 2025 | 779,000.00 |
| Dec 31, 2024 | 1.73 Mn |
| Dec 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Dec 31, 2022 | 1.20 Mn |
| Dec 31, 2022 | 1.20 Mn |
| Dec 31, 2021 | 1.14 Mn |
| Dec 31, 2021 | 1.14 Mn |
| Dec 31, 2020 | 117,000.00 |
| Dec 31, 2020 | 117,000.00 |
| Dec 31, 2019 | 127,000.00 |
| Dec 31, 2019 | 127,000.00 |
| Dec 31, 2018 | 22,000.00 |
| Dec 31, 2018 | 22,000.00 |
| Dec 31, 2016 | 20,482.00 |
| Dec 31, 2016 | 20,482.00 |
| Dec 31, 2015 | 19,271.00 |
| Dec 31, 2015 | 19,271.00 |